The infertility drug market is anticipated to grow as a result of increased research and development for more effective treatments with fewer side effects to reduce infertility. Due to growing research and development studies for more efficient treatments to induce conception and deliver live babies, the market for infertility medications is anticipated to expand significantly. For instance, a group of researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) discovered in 2014 that women taking Letrozole have higher rates of ovulation and live births than women taking the standard medication, Clomiphene. In addition, the incidence of lifestyle problems and poor eating habits including obesity, stress, smoking, diabetes, Poly Cystic Ovarian Syndrome (PCOS), and others is increasing, which contributes to an increase in the need for infertility medications. In comparison to nonsmokers in China, smoking was linked to a drop in sperm density of 15.3%, total sperm counts of 17.5%, and total motile sperm of 16.6%, according to a study published in the National Center for Biotechnology and Information (NCBI) 2015 report.
Coherent Market Insights estimates that the market for Infertility Drugs was valued at US$ 3.8 billion in 2017 and is anticipated to grow at a CAGR of 5.8% from 2019 to 2026.
Major Players in the Infertility Drugs Industry:
1. Abbott Laboratories
The company was started in 1888 and is based in Chicago, Illinois, United States. The business finds, creates, produces, and markets a diverse range of healthcare goods and services. Pharmaceuticals, nutritional, diagnostic, and vascular items are among the offerings of the company. Lingo, a series of consumer bio wearable sensors that collects a variety of biological measurements to optimise exercise and dietary plans, was released by Abbott in January 2022.
2. Bayer AG
The company was started in 1863 and is based in Leverkusen, Germany. Bayer AG manufactures and sells agricultural and medical products. The business announced its plans to purchase PSMA Therapeutics Inc. and Noria Therapeutics Inc. in June 2021. For $425 million, Bayer announced in August 2020 that it had purchased KaNDy Therapeutics Ltd, bolstering its female healthcare division.